Horizon Discovery Group plc (LSE:HZD) (“Horizon” or the “Company”), the world leader in the application of gene editing technologies, today announces that it has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.
By Vivien Diniz
Editas Medicine’s share price went on a tear following its IPO in February. In the last two days, however, it’s dropped 36 percent. Here’s why.